Glenmark Pharmaceuticals gets final approval for Propafenone Hydrochloride ER Capsules

From USFDA

Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (USFDA) for Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg, 325 mg, and 425 mg, the generic version of Rythmol SR Capsules, 225 mg, 325 mg, and 425 mg, of GlaxoSmithKline, LLC.

Powered by Capital Market - Live News